Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!
Lung Cancer at ASCO 2025
- Home
- asco conference 2025
- lung cancer abstracts asco 2025
Top Lung Cancer Abstracts | ASCO 2025
The ASCO 2025 conference is poised to highlight significant breakthroughs in lung cancer treatment. The Lung cancer treatment landscape continues to evolve rapidly. Progress spans from small molecules to monoclonal antibodies, bispecific antibodies, and Antibody-drug Conjugates (ADCs). These innovations reflect a broader understanding of tumor biology and biomarkers. Leading pharmaceutical companies, including Bristol Myers Squibb, Pfizer, Merck, AstraZeneca, Eli Lilly, Janssen, and Daiichi Sankyo, among others, are preparing to unveil clinical data of their lung cancer therapies, which are anticipated to spark considerable interest and discussion throughout the event.
Non-small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for about 85% of all cases. DelveInsight estimates that in 2024, there were approximately 538,000 new cases across the 7MM. The current treatment landscape for NSCLC is largely dominated by checkpoint inhibitors like KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab). The conference will showcase a diverse array of clinical trials data from novel drug classes, and mechanisms of action. Not only this, in the NSCLC space, ASCO 2025 will highlight outcomes across various subtypes, including EGFR/MET-expressing to KRAS-mutated patients Late-breaking abstract #LBA8000 will present an overall survival update from the CheckMate-816 trial (NCT02998528). The data are likely to further validate the lasting survival benefits of neoadjuvant OPDIVO and chemotherapy in resectable NSCLC, with key efficacy endpoints (event-free survival (EFS), pathologic complete response, and major pathologic response improvements) maintained beyond three years.
SCLC accounts for approximately 15% of all lung cancer cases. Even though NSCLC continues to dominate the lung cancer space in terms of the number of abstracts presented at the conference, however, the findings from the IMforte and DeLLphi-304 study are likely to draw considerable attention from several lung cancer experts. The IMforte study supports the use of ZEPZELCA in combination with TECENTRIQ as maintenance therapy in extensive-stage SCLC, potentially introducing a new treatment paradigm following induction chemoimmunotherapy. On the other hand, the phase III DeLLphi-304 primary analysis could mark a breakthrough in the historically difficult second-line SCLC treatment landscape.
The top abstracts within the niche of lung cancer from DelveInsight listed below hold promise for significant advancements, aiming to positively impact the lives of patients affected by lung cancers.
Lung Cancer Key Abstracts
|
Company/ Institute Name |
Drug Name |
Molecule Type |
Trial ID/ Acronym |
Patient Segment |
Phase |
Abstract ID |
Abstract Title |
|
Bristol Myers Squibb |
OPDIVO (nivolumab) + chemotherapy |
Monoclonal antibody |
NCT02998528 (CheckMate 816) |
Neo-adjuvant resectable NSCLC |
III |
#LBA8000 |
Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816 |
|
Amgen |
IMDELLTRA (tarlatamab) |
Bispecific T-cell engager (BiTE) |
NCT05740566 (DeLLphi-304) |
Second-line treatment for SCLC |
III |
#LBA8008 |
Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304. |
|
Johnson & Johnson Innovation Medicine |
RYBREVANT (amivantamab) + chemotherapy |
Bispecific antibody |
NCT04988295 (MARIPOSA-2) |
EGFR - locally advanced or metastatic NSCLC after osimertinib failure |
III |
#8639 |
Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2 |
|
Hoffmann-La Roche |
ZEPZELCA (lurbinectedin) + TECENTRIQ (atezolizumab) |
Small molecule + Monoclonal antibody |
NCT05091567 (IMforte) |
Extensive-stage SCLC |
III |
#8006 |
Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the Phase III IMforte trial |
|
Daiichi Sankyo |
Patritumab deruxtecan |
Antibody-drug Conjugate (ADC) |
NCT05338970 (HERTHENA-Lung02) |
EGFRm advanced NSCLC |
III |
#8506 |
Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The Phase III HERTHENA-Lung02 study |
|
AstraZeneca |
TAGRISSO (osimertinib) ± chemotherapy |
Small molecule |
NCT04351555 (NeoADAURA) |
Neo-adjuvant, EGFR+ resectable NSCLC |
III |
#8001 |
Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA |
|
AbbVie |
EMRELIS (telisotuzumab vedotin) |
Small molecule |
NCT03539536 (LUMINOSITY) |
c-Met+ NSCLC |
II |
#8618 |
LUMINOSITY, a Phase II study of telisotuzumab vedotin in patients with c-Met protein–overexpressing non-squamous EGFR-wildtype advanced NSCLC: Efficacy outcomes by prior therapy |
|
AstraZeneca |
TAGRISSO (osimertinib) + Savolitinib |
Small molecules |
NCT03778229 (SAVANNAH) |
EGFRm+/MET+ NSCLC |
II |
#8513 |
Efficacy and CNS results from a randomized subset of the Phase II SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO) |
|
Abion |
Vabametkib |
Small molecule |
NCT05541822 |
MET exon 14 skipping NSCLC |
II |
#8640 |
Vabametkib in MET exon 14 skipping non-small-cell lung cancer: Efficacy and safety from the open-label, Phase II, cohort-1 trial |
|
Eli Lilly |
Olomorasib |
Small molecule |
NCT04956640 (LOXO-RAS-20001) |
First line, KRAS G12C-mutant advanced NSCLC |
I/II |
#8519 |
Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial |
|
Mythic Therapeutics |
MYTX-011 |
ADC |
NCT05652868 (KisMET-01) |
Advanced NSCLC with cMET overexpression or MET amplification/exon 14 skipping mutations |
I |
#8613 |
MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the Phase I KisMET-01 study |
|
Merck |
MK-1084 |
Small molecule |
NCT05067283 (KANDLELIT-001) |
KRAS G12C- metastatic NSCLC |
I |
#8605 |
MK-1084 for KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC): Results from KANDLELIT-001 |
|
Daiichi Sankyo and AstraZeneca |
DATROWAY (datopotamab deruxtecan) |
ADC |
NCT04526691 (TROPION-Lung02) |
Advanced or metastatic NSCLC |
I |
#8501 |
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC) |
|
Daiichi Sankyo and AstraZeneca |
DATROWAY (datopotamab deruxtecan) |
ADC |
NCT04612751 (TROPION-Lung04) |
Advanced or metastatic NSCLC |
I |
#8521 |
First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5) |
|
AbbVie |
Telisotuzumab adizutecan |
ADC |
NCT05029882 |
Advanced EGFR non-squamous NSCLC |
I |
#8512 |
Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a Phase I study |
Executive Summary
The ASCO 2025 conference is poised to highlight significant breakthroughs in lung cancer treatment. The Lung cancer treatment landscape continues to evolve rapidly.